NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts ...
Galectin Therapeutics Inc. NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today ...
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...
In the May 6 Nature the investigators delved into the dynamics of LTA-α in atherosclerotic lesions, identifying a binding partner for LTA-α, the lectin galectin-2. In an evaluation of more than ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
At Galectin Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a ...